Literature DB >> 33078433

Safety, Tolerability, and Outcomes of Enteral Nutrition in Extracorporeal Membrane Oxygenation.

Robert C Davis1, Lucian A Durham2, Laszlo Kiraly3, Jayshil J Patel4.   

Abstract

Extracorporeal membrane oxygenation (ECMO) is a supportive care system for patients with respiratory or cardiac failure. Patients requiring ECMO are at risk for significant inflammation, prolonged hospitalization, and acquired malnutrition and sarcopenia. Societal guidelines recommend early enteral nutrition in critically ill patients; however, in this population, optimal timing and dose of nutrition remains unknown and fear of reduced splanchnic perfusion, delayed gastric emptying, and bowel ischemia poses a barrier to appropriate energy and protein intake. This narrative review intends to provide an overview of ECMO, highlight the rationale for nutrition support in this population, and review the safety, tolerability, and outcomes associated with enteral nutrition during ECMO.
© 2020 American Society for Parenteral and Enteral Nutrition.

Entities:  

Keywords:  critical illness; enteral nutrition; extracorporeal membrane oxygenation; nutrition support; patient safety; pulmonary ventilation

Year:  2020        PMID: 33078433     DOI: 10.1002/ncp.10591

Source DB:  PubMed          Journal:  Nutr Clin Pract        ISSN: 0884-5336            Impact factor:   3.080


  2 in total

1.  Early Enteral Nutrition and Gastrointestinal Complications in Pediatric Patients on Extracorporeal Membrane Oxygenation.

Authors:  Gema Pérez; Elena González; Laura Zamora; Sarah N Fernández; Amelia Sánchez; Jose María Bellón; María José Santiago; María José Solana
Journal:  J Pediatr Gastroenterol Nutr       Date:  2022-01-01       Impact factor: 3.288

2.  Nutrition support practices across the care continuum in a single centre critical care unit during the first surge of the COVID-19 pandemic - A comparison of VV-ECMO and non-ECMO patients.

Authors:  Georgia Hardy; Luigi Camporota; Danielle E Bear
Journal:  Clin Nutr       Date:  2022-09-10       Impact factor: 7.643

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.